nach oben

Current Dermatology Reports

Erschienen in:

01.03.2020 | Infectious Disease and Dermatology (C Beard and K. Krishnamurthy, SECTION EDITORS)

Risk, Prevention, Diagnosis, and Management of Cellulitis and Erysipelas

verfasst von: Richard J. Brindle, Louise A. O’Neill, O. Martin Williams

Erschienen in: Current Dermatology Reports | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review summarises the most recent evidence which will inform therapeutic guidance and discusses areas of uncertainty which might benefit from further investigation.

Recent Findings

There are variable definitions of cellulitis and erysipelas, and of recovery and cure, which make it difficult to combine results from studies. The etiology of cellulitis is more clearly associated with beta-hemolytic streptococci. The diagnosis can be more accurately made using scoring systems and measurements of skin surface temperature. Antibiotic therapy should be oral in most cases and need not be prolonged despite extensive skin damage. Prevention using antibiotic prophylaxis works but there is no sustained benefit after cessation.

Summary

There are areas of uncertainty which would benefit from further research: the roles of adjuvant therapies, the best analgesia, the best way of preventing recurrences whilst limiting antibiotic exposure, the dosing of antibiotics, and what criteria to use in deciding on hospital admission and parenteral therapy.

Peterson RA, Polgreen LA, Cavanaugh JE, Polgreen PM. Increasing incidence, cost, and seasonality in patients hospitalized for cellulitis. Open Forum Infect Dis. 2017;4(1):ofx008. https://doi.org/10.1093/ofid/ofx008.CrossRefPubMedPubMedCentral

Zhang X, Dang S, Ji F, Shi J, Li Y, Li M, et al. Seasonality of cellulitis: evidence from Google trends. Infect Drug Resist. 2018;11:689–93. https://doi.org/10.2147/IDR.S163290.CrossRefPubMedPubMedCentral

Marcelin JR, Challener DW, Tan EM, Lahr BD, Baddour LM. Incidence and effects of seasonality on nonpurulent lower extremity cellulitis after the emergence of community-acquired methicillin-resistant staphylococcus aureus. Mayo Clin Proc. 2017;92(8):1227–33. https://doi.org/10.1016/j.mayocp.2017.04.008.CrossRefPubMedPubMedCentral

Brindle R, Williams OM, Davies P, Harris T, Jarman H, Hay AD, et al. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. BMJ Open. 2017;7(3):e013260. https://doi.org/10.1136/bmjopen-2016-013260.CrossRefPubMedPubMedCentral

Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004;2(2):89–95.CrossRef

Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. Etiology of cellulitis and clinical prediction of streptococcal disease: a prospective study. Open Forum Infect Dis. 2016;3(1):ofv181. https://doi.org/10.1093/ofid/ofv181.CrossRefPubMed

• Rath E, Skrede S, Mylvaganam H, Bruun T. Aetiology and clinical features of facial cellulitis: a prospective study. Infect Dis (Lond). 2018;50(1):27–34. https://doi.org/10.1080/23744235.2017.1354130Shows that facial cellulitis is caused by the same range of beta-hemolytic streptococci as limb cellulitis and confirms that treatment can be short and with oral antibiotics. CrossRef

Komatsu Y, Okazaki A, Hirahara K, Araki K, Shiohara T. Differences in clinical features and outcomes between group A and group G streptococcus -induced cellulitis. Dermatology. 2015;230(3):244–9. https://doi.org/10.1159/000371813.CrossRefPubMed

Stevens DL, Bryant AE. Severe group a streptococcal infections. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City (OK); 2016. https://www.ncbi.nlm.nih.gov/books/NBK333424/.

10.

Trell K, Rigner S, Wierzbicka M, Nilson B, Rasmussen M. Colonization of beta-hemolytic streptococci in patients with erysipelas-a prospective study. Eur J Clin Microbiol Infect Dis. 2019;38(10):1901–6. https://doi.org/10.1007/s10096-019-03625-9.CrossRefPubMedPubMedCentral

11.

Montalto M, Davies F, Marijanovic N, Meads A. Skin surface temperature: a possible new outcome measure for skin and soft tissue infection. Aust Fam Physician. 2013;42(9):653–7.PubMed

12.

•• Ko LN, Raff AB, Garza-Mayers AC, Dobry AS, Ortega-Martinez A, Anderson RR, et al. Skin surface temperatures measured by thermal imaging aid in the diagnosis of cellulitis. J Invest Dermatol. 2018;138(3):520–6. https://doi.org/10.1016/j.jid.2017.09.022Summarises and assesses the value of objective measurements of skin surface temperature using thermal imaging which also allows accurate mapping of the affected area. CrossRefPubMed

13.

Hamill LM, Thi YE, Keijzers G. Picking the low-hanging fruit: why not choose oral antibiotics for skin and soft-tissue infections in the emergency department. Emerg Med Australas. 2019. https://doi.org/10.1111/1742-6723.13383.

14.

Blackberg A, Trell K, Rasmussen M. Erysipelas, a large retrospective study of aetiology and clinical presentation. BMC Infect Dis. 2015;15:402. https://doi.org/10.1186/s12879-015-1134-2.CrossRefPubMedPubMedCentral

15.

• Brindle RJ, Ijaz A, Davies P. Procalcitonin and cellulitis: correlation of procalcitonin blood levels with measurements of severity and outcome in patients with limb cellulitis. Biomarkers. 2019;24(2):127–30. https://doi.org/10.1080/1354750X.2018.1501764Demonstrates that procalcitonin values are often low in cellulitis and caution should be used in using it to decide on antibiotic therapy. CrossRefPubMed

16.

Toleman MS, Vipond IB, Brindle R. Specific PCR, bacterial culture, serology and pharyngeal sampling to enhance the aetiological diagnosis of cellulitis. J Med Microbiol. 2016;65(1):44–7. https://doi.org/10.1099/jmm.0.000191.CrossRefPubMed

17.

Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol. 1989;125(6):779–82.CrossRef

18.

Arakaki RY, Strazzula L, Woo E, Kroshinsky D. The impact of dermatology consultation on diagnostic accuracy and antibiotic use among patients with suspected cellulitis seen at outpatient internal medicine offices: a randomized clinical trial. JAMA Dermatol. 2014;150(10):1056–61. https://doi.org/10.1001/jamadermatol.2014.1085.CrossRefPubMed

19.

Weng QY, Raff AB, Cohen JM, Gunasekera N, Okhovat JP, Vedak P, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153(2):141–6. https://doi.org/10.1001/jamadermatol.2016.3816.CrossRefPubMed

20.

Patel M, Lee SI, Akyea RK, Grindlay D, Francis N, Levell NJ, et al. A systematic review showing the lack of diagnostic criteria and tools developed for lower-limb cellulitis. Br J Dermatol. 2019. https://doi.org/10.1111/bjd.17857.

21.

Raff AB, Weng QY, Cohen JM, Gunasekera N, Okhovat JP, Vedak P, et al. A predictive model for diagnosis of lower extremity cellulitis: a cross-sectional study. J Am Acad Dermatol. 2017;76(4):618–25 e2. https://doi.org/10.1016/j.jaad.2016.12.044.CrossRefPubMed

22.

•• Li DG, Dewan AK, Xia FD, Khosravi H, Joyce C, Mostaghimi A. The ALT-70 predictive model outperforms thermal imaging for the diagnosis of lower extremity cellulitis: a prospective evaluation. J Am Acad Dermatol. 2018;79(6):1076–80 e1. https://doi.org/10.1016/j.jaad.2018.06.062Assesses a scoring system for the diagnosis of cellulitis and shows that the addition of thermal imaging improves specificity.

23.

Singer S, Li DG, Gunasekera N, Okhovat JP, Vedak P, Weng C, et al. The ALT-70 predictive model maintains predictive value at 24 and 48 hours after presentation. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.03.050.

24.

Jain SR, Hosseini-Moghaddam SM, Dwek P, Gupta K, Elsayed S, Thompson GW, et al. Infectious diseases specialist management improves outcomes for outpatients diagnosed with cellulitis in the emergency department: a double cohort study. Diagn Microbiol Infect Dis. 2017;87(4):371–5. https://doi.org/10.1016/j.diagmicrobio.2016.12.015.CrossRefPubMed

25.

Li DG, Xia FD, Khosravi H, Dewan AK, Pallin DJ, Baugh CW, et al. Outcomes of early dermatology consultation for inpatients diagnosed with cellulitis. JAMA Dermatol. 2018;154(5):537–43. https://doi.org/10.1001/jamadermatol.2017.6197.CrossRefPubMedPubMedCentral

26.

Sutherland M, Parent A. Diagnosis and management of cellulitis: a dermatology perspective. Br J Commun Nurs. 2017;22(6):272–5. https://doi.org/10.12968/bjcn.2017.22.6.272.CrossRef

27.

Brindle R. Outpatient parenteral antimicrobial therapy in a changing NHS: challenges and opportunities. Clin Med (Lond). 2013;13(3):322. https://doi.org/10.7861/clinmedicine.13-3-322.CrossRef

28.

Durojaiye OC, Cartwright K, Ntziora F. Outpatient parenteral antimicrobial therapy (OPAT) in the UK: a cross-sectional survey of acute hospital trusts and health boards. Diagn Microbiol Infect Dis. 2019;93(1):58–62. https://doi.org/10.1016/j.diagmicrobio.2018.07.013.CrossRefPubMed

29.

(CREST) CREST. Guidelines on the management of cellulitis in adults. 2005. http://www.acutemed.co.uk/docs/Cellulitis%20guidelines,%20CREST,%2005.pdf. Accessed 12/06/2018 2018.

30.

Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):147–59. https://doi.org/10.1093/cid/ciu296.CrossRefPubMed

31.

Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52(Suppl 1):i3–17. https://doi.org/10.1093/jac/dkg466.CrossRefPubMed

32.

Cutfield T, Walter H, Hobbs M, Chuang A, Thomas MG, Ritchie SR. Association of the Dundee severity classification with mortality, length of stay and readmission in adult inpatients with cellulitis. J Antimicrob Chemother. 2019;74(1):200–6. https://doi.org/10.1093/jac/dky400.CrossRefPubMed

33.

•• Brindle R, Williams OM, Barton E, Featherstone P. Assessment of antibiotic treatment of cellulitis and erysipelas: a systematic review and meta-analysis. JAMA Dermatol. 2019. https://doi.org/10.1001/jamadermatol.2019.0884Summarises the evidence from clinical trials for antibiotics, their duration, and route.

34.

Smith E, Patel M, Thomas KS. Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. Br J Dermatol. 2018;178(5):1028–34. https://doi.org/10.1111/bjd.16235.CrossRefPubMed

35.

Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164(15):1669–74. https://doi.org/10.1001/archinte.164.15.1669.CrossRefPubMed

36.

• Cranendonk DR, Opmeer BC, van Agtmael MA, Branger J, Brinkman K, Hoepelman AIM, et al. Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomised, double-blind, placebo-controlled, non-inferiority trial. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2019.09.019Demonstrates the difficulties in recruiting patients to trials involving long courses of IV therapy.

37.

Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, et al. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013;368(18):1695–703. https://doi.org/10.1056/NEJMoa1206300.CrossRefPubMed

38.

Cranendonk DR, Opmeer BC, Prins JM, Wiersinga WJ. Comparing short to standard duration of antibiotic therapy for patients hospitalized with cellulitis (DANCE): study protocol for a randomized controlled trial. BMC Infect Dis. 2014;14:235. https://doi.org/10.1186/1471-2334-14-235.CrossRefPubMedPubMedCentral

39.

Clarke MC, Cheng AC, Pollard JG, Birch M, Cowan RU, Linke JA, et al. Lessons learned from a randomized controlled trial of short-course intravenous antibiotic therapy for erysipelas and cellulitis of the lower limb (SWITCH trial). Open Forum Infect Dis. 2019;6(9). https://doi.org/10.1093/ofid/ofz335.

40.

Nelson EA, Bell-Syer SE. Compression for preventing recurrence of venous ulcers. Cochrane Database Syst Rev. 2014;9:CD002303. https://doi.org/10.1002/14651858.CD002303.pub3.CrossRef

41.

Webb E, Neeman T, Gaida J, Bowden FJ, Mumford V, Bissett B. Impact of compression therapy on cellulitis (ICTOC) in adults with chronic oedema: a randomised controlled trial protocol. BMJ Open. 2019;9(8):e029225. https://doi.org/10.1136/bmjopen-2019-029225.CrossRefPubMedPubMedCentral

42.

Johnson S, Leak K, Singh S, Tan P, Pillay W, Cuschieri RJ, et al. Can cycloidal vibration plus standard treatment reduce lower limb cellulitis treatment times? J Wound Care. 2007;16(4):166–9. https://doi.org/10.12968/jowc.2007.16.4.27026.CrossRefPubMed

43.

• Davis JS, Mackrow C, Binks P, Fletcher W, Dettwiller P, Marshall C, et al. A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clin Microbiol Infect. 2017;23(4):242–6. https://doi.org/10.1016/j.cmi.2017.02.036This trial was unable to demonstrate any benefit from ibuprofen but it appears safe. CrossRefPubMed

44.

Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29(4):377–82. https://doi.org/10.3109/00365549709011834.CrossRefPubMed

45.

Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis. 1998;30(2):206–7. https://doi.org/10.1080/003655498750003708.CrossRefPubMed

46.

Goldstein SI, Damiron K, Dominici P. Utilization of single dose of oral prednisone in the treatment of cellulitis. Acad Emerg Med. 2016;21(S1):S27 (abstract 42).

47.

Davies BW, Smith JM, Hink EM, Durairaj VD. C-reactive protein as a marker for initiating steroid treatment in children with orbital cellulitis. Ophthalmic Plast Reconstr Surg. 2015;31(5):364–8. https://doi.org/10.1097/IOP.0000000000000349.CrossRefPubMed

48.

British Lymphology Society. Consensus document on the management of cellulitis in lymphoedema. 2015. https://www.lymphoedema.org/images/pdf/CellulitisConsensus.pdf. Accessed October 2019.

49.

Societe Francaise de Dermatologie. Erysipelas and necrotizing fasciitis [Erysipele et fasiite necrosante: Prise en charge]. Ann Dermatol Venereol. 2001;128:463–82.

50.

National Institute for Health Care Excellence. Cellulitis and erysipelas: antimicrobial prescribing (nice guideline 141). 2019. https://www.nice.org.uk/guidance/ng141. Accessed October 2019.

51.

Dong SL, Kelly KD, Oland RC, Holroyd BR, Rowe BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med. 2001;19(7):535–40. https://doi.org/10.1053/ajem.2001.28330.CrossRefPubMed

52.

Williams OM, Brindle RJ. South West Regional Microbiology G. Audit of guidelines for antimicrobial management of cellulitis across English NHS hospitals reveals wide variation. J Inf Secur. 2016;73(3):291–3. https://doi.org/10.1016/j.jinf.2016.06.002.CrossRef

53.

Lemaire X, Bonnet E, Castan B, Forestier E, Lescure FX, Roblot F, et al. Management of non-necrotizing cellulitis in France. Med Mal Infect. 2016;46(7):355–9. https://doi.org/10.1016/j.medmal.2016.04.005.CrossRefPubMed

54.

Davies MS, Robertson MB, Brown SH, Saunders B, Waring WS. Variability of antimicrobial prescribing in patients with acute cellulitis. Eur J Clin Pharmacol. 2012;68(9):1303–7. https://doi.org/10.1007/s00228-012-1240-7.CrossRefPubMed

55.

Quirke M, Saunders J, O’Sullivan R, Wakai A. The management of cellulitis in emergency departments: antibiotic-prescribing practices and adherence to practice guidelines in Ireland. Eur J Emerg Med. 2016;23(3):173–8. https://doi.org/10.1097/MEJ.0000000000000245.CrossRefPubMed

56.

Sullivan T, de Barra E. Diagnosis and management of cellulitis. Clin Med (Lond). 2018;18(2):160–3. https://doi.org/10.7861/clinmedicine.18-2-160.CrossRef

57.

• Quirke M, Ayoub F, McCabe A, Boland F, Smith B, O’Sullivan R, et al. Risk factors for nonpurulent leg cellulitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(2):382–94. https://doi.org/10.1111/bjd.15186Summarises the risk factors associated with cellulitis. CrossRefPubMed

58.

Eells SJ, Chira S, David CG, Craft N, Miller LG. Non-suppurative cellulitis: risk factors and its association with staphylococcus aureus colonization in an area of endemic community-associated methicillin-resistant S.aureus infections. Epidemiol Infect. 2011;139(4):606–12. https://doi.org/10.1017/S0950268810001408.CrossRefPubMed

59.

•• Dalal A, Eskin-Schwartz M, Mimouni D, Ray S, Days W, Hodak E, et al. Interventions for the prevention of recurrent erysipelas and cellulitis. Cochrane Database Syst Rev. 2017;6:CD009758. https://doi.org/10.1002/14651858.CD009758.pub2This meta-analysis summarises the effect of antibiotic prophylaxis but is dominated by two trials from one center. CrossRefPubMed

60.

U. K. Dermatology Clinical Trials Network’s PATCH Trial Team, Thomas K, Crook A, Foster K, Mason J, Chalmers J, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network’s PATCH II trial. Br J Dermatol. 2012;166(1):169–78. https://doi.org/10.1111/j.1365-2133.2011.10586.x.CrossRefPubMedCentral

61.

Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209(4):301–7. https://doi.org/10.1159/000080853.CrossRefPubMed

62.

Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010;6:CD004299. https://doi.org/10.1002/14651858.CD004299.pub2.CrossRef

63.

Gunderson CG, Cherry BM, Fisher A. Do patients with cellulitis need to be hospitalized? A systematic review and meta-analysis of mortality rates of inpatients with cellulitis. J Gen Intern Med. 2018;33(9):1553–60. https://doi.org/10.1007/s11606-018-4546-z.CrossRefPubMedPubMedCentral

64.

Morgenstern J. Magical thinking in modern medicine: IV antibiotics for cellulitis. Published April 2, 2018-Updated 8 March 2019. https://first10em.com/cellulitis-antibiotics/. Accessed 30 Sept 2019.

65.

Thomas KS, Brindle R, Chalmers JR, Gamble B, Francis NA, Hardy D, et al. Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership. Br J Dermatol. 2017;177(2):541–3. https://doi.org/10.1111/bjd.15634.CrossRefPubMed

Titel: Risk, Prevention, Diagnosis, and Management of Cellulitis and Erysipelas
verfasst von: Richard J. Brindle
Louise A. O’Neill
O. Martin Williams
Publikationsdatum: 01.03.2020
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 1/2020
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-020-00287-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Sunscreen Safety: a Review of Recent Studies on Humans and the Environment

Teledermatology for Skin Cancer: The Australian Experience

Bimekizumab

Update on Sleep and Pulmonary Comorbidities in Psoriasis

Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Molluscum Contagiosum: Review and Update on Clinical Presentation, Diagnosis, Risk, Prevention, and Treatment